In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback